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Background: The purpose of this study was to evaluate the dynamics of plasma melatonin 
secretion in patients with type 2 diabetes mellitus and diabetic retinopathy.
Methods: Plasma melatonin levels were measured by high-performance liquid chromatography 
in 56 patients. Patients were divided into a diabetic group (30 patients) and a nondiabetic group 
(26 patients). The diabetic group was divided further into a proliferative diabetic retinopathy 
(PDR) group (n = 14) and a nonproliferative diabetic retinopathy (NPDR) group (n = 16). Plasma 
melatonin levels obtained at midnight and 3 am were compared between the groups.
Results: Nighttime melatonin levels were significantly lower in the diabetic group than in the 
nondiabetic group (P , 0.03) and lower in the PDR group than in the nondiabetic and NPDR 
groups (P , 0.01 and P , 0.03, respectively), but no significant difference was found between the 
nondiabetic and NPDR groups. The daytime melatonin level did not significantly differ between 
the nondiabetic and diabetic groups or between the nondiabetic, NPDR, and PDR groups.
Conclusion: The nighttime melatonin level is altered in patients with diabetes and PDR but not 
in diabetic patients without PDR. Although patients with PDR may have various dysfunctions 
that affect melatonin secretion more severely, advanced dysfunction of retinal light perception 
may cause altered melatonin secretion. Alteration of melatonin secretion may accelerate further 
occurrence of complications in diabetic patients.
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Introduction
Melatonin, an indoleamine hormone, is synthesized by pinealocytes, retinal photorecep-
tors, and ciliary epithelial cells.1,2 The pineal gland secretes melatonin into the circula-
tion almost entirely at night in vertebrates.2,3 The retinal perception of environmental 
light and dark cycles is transmitted to the suprachiasmatic nucleus via the retinohypo-
thalamic tract. Inhibitory information carried by the axons from the suprachiasmatic 
nucleus is transferred to the autonomic division of the paraventricular nucleus and the 
brainstem areas involved in sympathetic preganglionic outflow. The axons of these 
neurons are connected to the intermediolateral cell column of the spinal cord, which 
carries input to the superior cervical ganglia, which is the primary source of pineal 
innervation.4,5 This complex pathway of environmental light/dark signal transduction 
is important for the circadian rhythmicity of melatonin secretion.
Melatonin physiology in diabetes mellitus has been examined. Animal and human 
studies have documented decreased plasma melatonin levels in diabetes.6–12 Chronic 
complications of diabetes, especially retinopathy and autonomic neuropathy, would 
be expected to affect nocturnal melatonin secretion. Ha et al13 investigated the effect Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Dovepress
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of melatonin on signaling pathways for glucose transport 
in mouse skeletal muscle cells, and demonstrated that 
melatonin stimulated glucose transport to skeletal muscle 
cells via the IRS-1/PI-3 kinase pathway, which implies, 
at the molecular level, its role in glucose homeostasis and 
possibly in diabetes. Additionally, exposure to light at night 
and aging, both of which lower endogenous melatonin 
levels, may contribute to the incidence and/or development 
of diabetes. Furthermore, Contreras-Alcantara et al14 have 
demonstrated recently that removal of the type 1 melatonin 
receptor (MT1) significantly impairs the ability of mice to 
metabolize glucose, probably due to increased insulin resis-
tance, and suggesting that MT1 receptors are implicated in 
the pathogenesis of type 2 diabetes. This research paved the 
way for detailed exploration of the mechanisms by which 
MT1 receptor signaling might affect glucose metabolism. 
However, we did not find any publications on altered mela-
tonin levels in diabetic patients with and without retinopathy 
in the scientific literature. In the present study, we examined 
plasma melatonin secretion in patients with type 2 diabetes 
and diabetic retinopathy.
Materials and methods
subjects
Fifty-six patients hospitalized at Ohtsuka Eye Hospital 
to undergo eye surgery participated in this study. Written 
informed consent was obtained from all patients, and the 
study adhered to the tenets of the Declaration of Helsinki. 
The 56 patients were divided into two groups, ie, a dia-
betic group comprising 30 patients with type 2 diabetes, 
and a nondiabetic group, comprising 26 patients whose 
biochemical and physiologic parameters (serum glucose, 
complete blood and platelet counts, liver enzymes, serum 
creatinine level, hemoglobin A1c [HbA1c], dipstick urine 
analysis, and electrocardiography) were within normal 
limits, and with no history of cardiac events. The diabetic 
group was further divided into patients with proliferative 
diabetic retinopathy (PDR, n = 14) and nonproliferative 
diabetic retinopathy (NPDR, n = 16), including those with no 
retinopathy and mild NPDR. Retinopathy was documented 
during a standard fundus examination in all patients, who 
underwent fluorescein angiography if necessary to evalu-
ate the presence of retinal neovascularization. Exclusion 
criteria included cigarette smoking, sleep disorders (includ-
ing obstructive sleep apnea), systemic disease or cardiac 
arrhythmia, and concomitant drugs affecting the autonomic 
nervous system, including α- and β-adrenergic receptor 
blockers and other sympatholytic agents, antidepressants, 
and anorectics. Renal function was assessed by serum levels 
of blood urea nitrogen and creatinine and by measuring for 
microalbuminuria. Peripheral polyneuropathy was evaluated 
by the same experienced endocrinologist, and was defined 
by the presence of symptoms, including pain, numbness, and 
paresthesia, and the absence of ankle reflexes.
Patients in the nondiabetic group and the NPDR group 
were admitted to hospital to undergo cataract surgery and 
those in the PDR group were admitted to undergo vitreous 
surgery combined with cataract surgery for massive vitreous 
hemorrhage, tractional retinal detachment, or both, associated 
with PDR. The lights in the hospital were turned off at 9 pm 
and turned on at 6 am.
Circadian fluctuations in melatonin were assessed by 
drawing blood in dim light (0 lux) via an indwelling can-
nula from an antecubital vein for measurement of mela-
tonin levels at midnight and 12.30 am while the patients 
were sleeping, and in the afternoon between 3 pm and 
3.30 pm. Particular attention was paid to allowing the 
participants to remain asleep during the midnight blood 
collection. Blood samples were obtained from all patients 
2 days after surgery. Plasma melatonin was measured by 
high-performance liquid chromatography in all patients. 
This method has proven reproducibility and can detect a 
0.5 pg/mL plasma concentration of melatonin, which is 
a lower value than that of the lowest circadian level of 
melatonin. Our preliminary study showed that the plasma 
concentration of melatonin obtained from five nondiabetic 
volunteers peaked at around midnight and was lowest at 
around 3 pm (Figure 1).
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Figure 1 Typical circadian fluctuations in plasma melatonin from five nondiabetic 
volunteers.  The  plasma  concentration  of  melatonin  reached  its  highest  level  at 
around midnight and lowest at around 3 pm. Vertical lines are one standard error 
of the means.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Clinical and laboratory characteristics of each group of study patients
Diabetic Nondiabetic
NPDR PDR
Patients (n) 30 16 14 26
Age (years) 65 ± 10 72 ± 8 56 ± 12 66 ± 11
gender (M/F) 11/19 5/11 6/8 10/16
Duration (years)  
from diagnosis of DM
12 ± 6 14 ± 7 10 ± 6 –
HbA1c (%) 6.8 ± 2.4 7.1 ± 3.2 6.4 ± 1.3 –
Diabetes treatment
  Diet only 1 (3%) 1 (6%) 0 (0%) –
  Oral drug 23 (77%) 12 (75%) 11 (79%) –
  insulin 6 (20%) 3 (19%) 3 (21%) –
increased BUn
  And/or creatinine 7 (23%) 2 (13%) 5 (36%) –
  Microalbuminuria 8 (27%) 3 (19%) 5 (36%) –
  Distal polyneuropathy 9 (30%) 3 (19%) 6 (43%) –
  Body mass index 27.5 ± 3.2 28.1 ± 3.5 27.0 ± 3.0 24.6 ± 3.4
Log MAr VA
  Better eye 0.30 ± 0.32 0.13 ± 0.10 0.51 ± 0.36 0.11 ± 0.09
  Worse eye 0.88 ± 0.70 0.31 ± 0.20 1.53 ± 0.40 0.27 ± 0.15
Mean decimal VA*
  Better eye 0.50 0.75 0.30 0.79
  Worse eye 0.14 0.49 0.03 0.53
Melatonin
  nighttime (pg/mL) 20.4 ± 22.3 31.1 ± 26.5 10.9 ± 11.4 37.5 ± 30.8
  Daytime (pg/mL) 0.8 ± 0.7 1.1 ± 0.6 0.4 ± 0.7 2.4 ± 4.1
Note: *Mean decimal VA was converted from mean logMAr VA.
Abbreviations: BUn, blood urea nitrogen; DM, diabetes; nPDr, nonproliferative diabetic retinopathy; HbA1c, glycosylated hemoglobin; VA, visual acuity; Log MAr, 
minimum angle of resolution; PDr, proliferative diabetic retinopathy.
statistical analysis
The differences between the patient groups were assessed 
for statistical significance using Student’s t-test or repeated-
measures analysis of variance as appropriate. The results are 
expressed as the mean ± standard deviation unless otherwise 
indicated. Analysis was conducted using the SPSSfor Win-
dows software package (v 11.5.1; SPSS Inc, Chicago, IL). 
P , 0.05 was considered statistically significant.
Results
The clinical and laboratory characteristics of the patients are 
shown in Table 1. No significant differences were found for 
age or gender between the groups. All women in this study 
were postmenopausal and not receiving hormone therapy. All 
patients in the PDR group had undergone bilateral panretinal 
photocoagulation.
The minimum angle of resolution (log MAR) visual 
acuities converted from patients’ Randolt rings showed that 
best-corrected visual acuities for the better and worse eyes 
were significantly better in the nondiabetic group than in the 
diabetic group (P , 0.01, respectively, Student’s t-test) and 
the PDR group (P , 0.01, respectively, repeated-measures 
analysis of variance), whereas no significant difference was 
found between the nondiabetic and NPDR groups (Table 1). 
In the PDR group, the logMAR visual acuity of the worse 
eye was significantly lower compared with the NPDR group 
(P , 0.01, repeated-measures analysis of variance), but the 
logMAR visual acuities of the better eye did not differ sig-
nificantly between the PDR and NPDR groups.
In the diabetic group, the percentages of patients who 
used insulin or had diabetic neuropathy and peripheral poly-
neuropathy did not differ significantly between the NPDR and 
PDR groups. There was no significant difference in HbA1c 
between the NPDR and PDR groups (Table 1).
The nighttime and daytime melatonin levels were 
35.5 ± 33.4 pg/mL and 2.8 ± 3.0 pg/mL in the nondiabetic 
group, 23.6 ± 30.1 and 1.0 ± 0.9 pg/mL in the diabetic group, 
34.8 ± 37.4 and 1.33 ± 0.7 pg/mL in the NPDR group, and 
10.9 ± 11.4 and 0.7 ± 0.9 pg/mL in the PDR group (Figures 2 
and 3). The nighttime melatonin level was significantly 
lower in the diabetic group than in the nondiabetic group 
(P , 0.03, Student’s t-test) and in the PDR group than in 
the nondiabetic and NPDR groups (P , 0.01 and P , 0.03, 
repeated-measures analysis of variance), but no significant Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Experimental diabetes resulted in decreased synthesis of 
melatonin from pinealocytes and decreased activity of 
hydroxyindole-O-methyltransferase, which is a key enzyme 
in melatonin synthesis.8,9 Recent publications confirm a func-
tional interrelationship between melatonin and insulin, and a 
reduction of melatonin in the genesis of diabetes.11,12,15–18
Although Tutuncu et al10 reported that the circadian 
rhythm of melatonin secretion was deteriorated in patients 
with type 2 diabetes and that there was a complex relation-
ship between various components of the autonomic nervous 
system and nighttime melatonin secretion, they did not find 
a difference in the melatonin levels of diabetic patients with 
and without retinopathy, and suggested that a small number 
of patients with PDR but without advanced retinopathy might 
have masked the effect of diabetic retinopathy on melatonin 
physiology in their study. The retinal perception of environ-
mental light and dark cycles is transmitted to the autonomic 
nerve system and finally to the pineal gland. Thus, disordered 
melatonin secretion induced by autonomic neuropathy seems 
reasonable.
Shanahan et al19 emphasized the importance of consider-
ing both phase and amplitude when describing the resetting 
of the human circadian pacemaker such as melatonin and 
temperature rhythms by light. Output signals from the supra-
chiasmatic nucleus regulate mRNA levels of pineal arylal-
kylamine N-acetyltransferase, a key enzyme in the melatonin 
synthesis pathway. Nocturnal upregulation of arylalkylamine 
N-acetyltransferase mRNA is the main cause for increased 
melatonin synthesis at night.20,21 Light is the most prevalent 
environmental stimulus that synchronizes the circadian 
pacemaker at the suprachiasmatic nucleus. In addition, light 
exerts direct effects on many of the pacemaker’s rhythmic 
outputs, including melatonin release. Schwartz et al22 showed 
that entrainment of the circadian rhythm of melatonin release 
could indeed be dissociated from its inhibition by light.
In the current study, visual acuities in both eyes were 
significantly worse in the PDR groups, which may indi-
cate dysfunctional retinal light perception. Moreover, all 
patients in the PDR group had undergone bilateral panretinal 
photocoagulation. Although panretinal photocoagulation is an 
established treatment to prevent retinal neovascularization,23 
the photocoagulated retinal and choroidal lesions are dam-
aged anatomically and functionally.24 Retinal dysfunction 
induced not only by advanced diabetic retinopathy but also 
by panretinal photocoagulation should be associated with 
diminished retinal light perception. Bughi et al25 reported that 
bilateral photocoagulation for PDR may be associated with 
loss of normal circadian cortisol variation. Therefore, not 
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Figure 2 nighttime melatonin levels in each group. The nighttime melatonin level 
differed significantly between the nondiabetic (n = 26) and diabetic groups (n = 30, 
P , 0.03, student’s t-test), and that level was significantly lower in the proliferative 
diabetic retinopathy group (n = 14) than in the nondiabetic and nonproliferative 
diabetic retinopathy groups (n = 16, P , 0.01 and P , 0.03, repeated-measures 
analysis of variance), but no significant difference was found between the nondiabetic 
and nonproliferative diabetic retinopathy groups.
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Figure 3 Daytime melatonin levels in each group. The daytime melatonin level 
did not significantly differ between the nondiabetic (n = 26) and diabetic groups 
(n = 30) or among the nondiabetic, nonproliferative diabetic retinopathy (n = 16), 
and proliferative diabetic retinopathy (n = 14) groups.
difference was found between the nondiabetic and NPDR 
groups. The daytime melatonin level did not significantly dif-
fer between the nondiabetic and diabetic groups, or between 
the nondiabetic, NPDR, and PDR groups.
Discussion
To the best of our knowledge, this is the first study to evalu-
ate the relationship between melatonin levels and diabetic 
retinopathy. Our results show that alteration of nighttime 
melatonin level was more apparent in patients with PDR. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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only severe diabetic retinopathy may be contributing to the 
decreased nighttime melatonin level, but also a significantly 
decreased area of functioning rods in lasered retinas. Lockley 
et al26 reported that most blind people without light percep-
tion had a circadian rhythm disorder. On the contrary, all 
patients without PDR in the current study were planning to 
undergo cataract surgery to improve visual acuity, ie, visual 
disturbance was considered to be the result of cataract and 
nondiabetic retinopathy in these patients. Thus, the degree of 
visual dysfunction induced by diabetic retinopathy should have 
been mild in these patients. Moreover, visual acuities of the 
better eyes were superior to those of PDR patients and visual 
acuities of the worse eyes, and these findings were similar 
to those in nondiabetic patients. Thus, cataracts in patients 
without PDR did not disrupt photic transmission to the retina 
and suprachiasmatic nucleus.
This preliminary study provides data showing disturbed 
melatonin secretion in patients with PDR. We also speculated 
that if advanced bilateral dysfunction of retinal light percep-
tion alters melatonin secretion, patients with decreased visual 
acuities in both eyes resulting from other disorders may also 
have dysfunctional melatonin secretion. Although panretinal 
photocoagulation, which is an essential treatment for PDR, 
may overestimate disturbed melatonin secretion in patients 
with PDR, advanced diabetic retinopathy seems to be an 
important factor for decreased melatonin secretion.
Limitations of this study were its small sample size and 
the standard deviations of the mean plasma concentrations of 
melatonin being large. Because plasma melatonin concentra-
tions were measured at only two time points during 24 hours 
in each subject, we could not demonstrate the entire rhythm of 
melatonin secretion over 24 hours in each subject. However, it 
is unclear as to what phase of the rhythm this midnight sample 
refers to because it is difficult to know the typical sleep times 
for each subject in the current study, and frequent drawing 
of blood during sleeping time in the hospital would not be 
allowed by the institutional review board at Ohtsuka Eye 
Hospital. Further and more detailed studies in a large number 
of diabetic participants with various diabetic complications 
are needed to determine their melatonin depletion status and 
its consequences in terms of biorhythm imbalances.
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